Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | PD1 |
Clinical data | |
Other names | SHR-1210 |
ATC code |
|
Identifiers | |
CAS Number | |
UNII |
Camrelizumab (SHR-1210) (INN[1]) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.[2]
This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019[update], camrelizumab is undergoing Phase II/III trials.
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |